Ocugen, Inc/$OCGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
$OCGN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
95
ISIN
US67577C1053
Website
Ocugen, Inc Metrics
BasicAdvanced
$301M
-
-$0.21
4.24
-
Price and volume
Market cap
$301M
Beta
4.24
52-week high
$1.98
52-week low
$0.52
Average daily volume
6.1M
Financial strength
Current ratio
2.604
Quick ratio
2.239
Long term debt to equity
195.344
Total debt to equity
199.969
Interest coverage (TTM)
-62.41%
Profitability
EBITDA (TTM)
-54.344
Gross margin (TTM)
-476.87%
Net profit margin (TTM)
-1,271.12%
Operating margin (TTM)
-1,261.43%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-61.33%
Return on equity (TTM)
-248.97%
Valuation
Price to revenue (TTM)
63.706
Price to book
18.9
Price to tangible book (TTM)
18.9
Price to free cash flow (TTM)
-5.545
Free cash flow yield (TTM)
-18.03%
Free cash flow per share (TTM)
-18.58%
Growth
Revenue change (TTM)
-31.56%
Earnings per share change (TTM)
-10.42%
3-year earnings per share growth (CAGR)
-16.19%
What the Analysts think about Ocugen, Inc
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Bulls say / Bears say
Ocugen's lead candidate, OCU400, has shown a favorable safety and tolerability profile in subjects with retinitis pigmentosa and Leber congenital amaurosis, with Phase 3 trials set to commence in early 2024. (gurufocus.com)
The company's inhaled mucosal vaccine candidate for COVID-19, OCU500, has been selected for inclusion in clinical trials by the NIH/NIAID Project NextGen, highlighting its potential in addressing respiratory viral diseases. (gurufocus.com)
Ocugen successfully closed a $35 million public offering of common stock in August 2024, bolstering its financial position to support ongoing and future clinical programs. (ir.ocugen.com)
Ocugen reported a net loss of $14.16 million for Q3 2023, indicating ongoing financial challenges. (marketscreener.com)
The company announced accounting errors related to agreements with a business partner, leading to plans to restate financial statements for 2022 and delaying key filings. (bloomberglaw.com)
Ocugen is facing a proposed class action lawsuit alleging materially false and misleading statements about its financials, which could impact investor confidence. (bloomberglaw.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Ocugen, Inc Financial Performance
Revenues and expenses
Ocugen, Inc Earnings Performance
Company profitability
Ocugen, Inc News
AllArticlesVideos
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
GlobeNewsWire·5 days ago
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewsWire·2 weeks ago
Ocugen To Present at BIO International Convention 2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocugen, Inc stock?
Ocugen, Inc (OCGN) has a market cap of $301M as of June 28, 2025.
What is the P/E ratio for Ocugen, Inc stock?
The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of June 28, 2025.
Does Ocugen, Inc stock pay dividends?
No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Ocugen, Inc dividend payment date?
Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocugen, Inc?
Ocugen, Inc (OCGN) has a beta rating of 4.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.